- Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)
- Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse
- Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit
- Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
- Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
- Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
- Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
- Allogene Therapeutics Announces Q2 Investor Conference Participation
- Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
- Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
More ▼
Key statistics
As of last trade, Allogene Therapeutics Inc (ALLO:NSQ) traded at 3.01, 49.50% above the 52 week low of 2.01 set on Jul 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.03 |
---|---|
High | 3.12 |
Low | 2.93 |
Bid | 3.00 |
Offer | 3.01 |
Previous close | 3.08 |
Average volume | 3.64m |
---|---|
Shares outstanding | 208.38m |
Free float | 153.12m |
P/E (TTM) | -- |
Market cap | 641.82m USD |
EPS (TTM) | -1.78 USD |
Data delayed at least 15 minutes, as of Jul 24 2024 18:23 BST.
More ▼